Red Flags Detected
- Going Concern (new) — Company now discloses substantial doubt about ability to continue as a going concern; cash runway insufficient for twelve months despite equity raises.
- Securities Litigation (new) — Three new lawsuits (one class action, two derivative) allege material misstatements about briquilimab clinical studies; no loss accrued.
Jasper cuts workforce 66%, exits stem-cell programs, raises going-concern flag
Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 28, 2025 · ~2 min read
Key Changes
-
high
Company disclosed substantial doubt about ability to continue as a going concern; cash fell from $71.6M to $28.7M despite $34M equity raise, insufficient to fund operations twelve months.
Risk Factors / MD&A: Liquidity verify on EDGAR → -
high
Strategic pivot announced alongside 66% workforce reduction (64 to 22 employees), discontinued stem-cell transplant programs (SCID, FA, SCD, CGD, GATA-2), halted asthma enrollment, and vivarium closure, suggesting aspirational rather than executed positioning in mast-cell diseases.
Business / MD&A: Restructuring verify on EDGAR → -
high
Three securities lawsuits filed alleging misstatements about briquilimab clinical studies; company denies merit but acknowledges litigation will impose costs and divert management resources.
Legal Proceedings verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SMID 10-Q) is open in full — no account needed.
Partner
Trade JSPRW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 11, 2026 2:32 AM